Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus

Roche awaits an FDA decision on Tecentriq for postoperative colon-cancer treatment on October 9, while multiple gene-therapy companies including Rocket Pharmaceuticals, RegenXBio, and uniQure will present updates at a key industry conference. Lilly received FDA approval for expanded use of its leukemia drug Jaypirca, and Ocular Therapeutix plans a fourth-quarter FDA filing for its eye-treatment Axpaxli.

This Wire brief sits within Fusion42's coverage of Biotech.